TY - JOUR T1 - Differential Interactions Between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern JF - bioRxiv DO - 10.1101/2021.07.23.453598 SP - 2021.07.23.453598 AU - Seonghan Kim AU - Yi Liu AU - Zewei Lei AU - Jeffrey Dicker AU - Yiwei Cao AU - X. Frank Zhang AU - Wonpil Im Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/07/26/2021.07.23.453598.abstract N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the current coronavirus disease 2019 (COVID-19) pandemic. It is known that the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 interacts with the human angiotensin-converting enzyme 2 (ACE2) receptor, initiating the entry of SARS-CoV-2. Since its emergence, a number of SARS-CoV-2 variants have been reported, and the variants that show high infectivity are classified as the variants of concern according to the US CDC. In this study, we performed both all-atom steered molecular dynamics (SMD) simulations and microscale thermophoresis (MST) experiments to characterize the binding interactions between ACE2 and RBD of all current variants of concern (Alpha, Beta, Gamma, and Delta) and two variants of interest (Epsilon and Kappa). We report that the RBD of the Alpha (N501Y) variant requires the highest amount of force initially to be detached from ACE2 due to the N501Y mutation in addition to the role of N90-glycan, followed by Beta/Gamma (K417N/T, E484K, and N501Y) or Delta (L452R and T478K) variant. Among all variants investigated in this work, the RBD of the Epsilon (L452R) variant is relatively easily detached from ACE2. Our results combined SMD simulations and MST experiments indicate what makes each variant more contagious in terms of RBD and ACE2 interactions. This study could help develop new drugs to inhibit SARS-CoV-2 entry effectively.TOC GraphicCompeting Interest StatementThe authors have declared no competing interest. ER -